BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
New nesting beach for birds at RSPB reserve- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- 2 new malaria treatments announced as drug resistance grows
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Figure out How to Pick the Right Dental specialist for Your Dental Inserts
- German state railway loss widens, passengers warned of trouble ahead
- Sixteen Kenyans missing in Russia after army recruitment
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
